HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Celebrex Cardiovascular Safety Trial Will Allow Acetaminophen Use

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Pfizer believes that allowing patients to take non-NSAID pain relievers, such as acetaminophen, in a trial evaluating the cardiovascular risk profile of Celebrex (celecoxib) will make a long-term placebo-controlled study in the arthritis population feasible

You may also be interested in...



Merck Defends Inaction on Vioxx VIGOR Data, Cites Naproxen Heart Benefit

Merck continues to support the cardioprotective effect of the non-steroidal anti-inflammatory drug naproxen

Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers

OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)

NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx

OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Cosmetic And Personal Care Trademark Review: 16 April

Health And Wellness Weekly Trademarks Review: 16 April

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Prestige Expands UK Eye Care Range In Response To Consumer Demand

See All
UsernamePublicRestriction

Register

RS128390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By